Desprez Charlotte, Damon Henri, Meurette Guillaume, Mege Diane, Faucheron Jean-Luc, Brochard Charlène, Lambrescak Elsa, Gourcerol Guillaume, Mion Francois, Wyart Vincent, Sielezneff Igor, Siproudhis Laurent, Etienney Isabelle, Ajamie Nadine, Lehur Paul-Antoine, Duflot Thomas, Bridoux Valérie, Leroi Anne-Marie
Department of Digestive Physiology, Rouen, France.
University Hospital of Lyon, Hospices Civils de Lyon, Digestive Physiology, Edouard Herriot Hospital, Lyon, France.
Ann Surg. 2022 Apr 1;275(4):735-742. doi: 10.1097/SLA.0000000000004251.
The aim of this study was to assess the effectiveness of sacral nerve modulation (SNM) in a large cohort of patients implanted for at least 10 years, quantify adverse event rates, and identify predictive factors of long-term success.
Few studies have evaluated the long-term success of SNM.
Data collected prospectively from patients implanted for fecal incontinence (FI) in 7 French centers between January 1998 and December 2008 were retrospectively analyzed. Patient FI severity scores were assessed before and 10 years after implantation. The main evaluation criterion was the success of SNM defined by the continuation of the treatment without additional therapies. The secondary evaluation criteria were the rate of device revisions and explantations. Preoperative predictors of success at 10 years were sought.
Of the 360 patients (27 males, mean age: 59 ± 12 years) implanted for FI, 162 (45%) had a favorable outcome 10 years post-implantation, 115 (31.9%) failed, and 83 (23.1%) were lost to follow-up. The favorable outcome derived from the time-to-event Kaplan-Meier curve at 10 years was 0.64 (95% CI 0.58-0.69). FI severity scores were significantly better 10 years post-implantation compared to preimplantation (7.4 ± 4.3 vs 14.0 ± 3.2; P < 0.0001). During the 10-year follow-up, 233 patients (64.7%) had a surgical revision and 94 (26.1%) were explanted. A history of surgery for FI and sex (male) were associated with an increased risk of an unfavorable outcome.
Long-term efficacy was maintained in approximately half of the FI patients treated by SNM at least 10 years post-implantation.
本研究旨在评估在至少植入10年的大量患者队列中骶神经调节(SNM)的有效性,量化不良事件发生率,并确定长期成功的预测因素。
很少有研究评估SNM的长期成功率。
回顾性分析1998年1月至2008年12月期间在法国7个中心为治疗大便失禁(FI)而植入装置的患者前瞻性收集的数据。在植入前和植入后10年评估患者的FI严重程度评分。主要评估标准是SNM的成功,定义为无需额外治疗即可继续治疗。次要评估标准是设备翻修和取出率。寻找10年成功的术前预测因素。
在为FI植入装置的360例患者(27例男性,平均年龄:59±12岁)中,162例(45%)在植入后10年有良好结局,115例(31.9%)失败,83例(23.1%)失访。10年时事件发生时间的Kaplan-Meier曲线得出的良好结局为0.64(95%CI 0.58-0.69)。与植入前相比,植入后10年FI严重程度评分显著改善(7.4±4.3对14.0±3.2;P<0.0001)。在10年随访期间,233例患者(64.7%)进行了手术翻修,94例(26.1%)装置被取出。FI手术史和性别(男性)与不良结局风险增加相关。
在植入后至少10年接受SNM治疗的FI患者中,约一半维持了长期疗效。